Business
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest
About this update from Quidelortho Corporation
[{"type":"text","content":"RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (“Quidel”) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the “BCA”). The closing of the transactions contemplated by the BCA is subject to sanction of the combination by the High Court of Justice of England and Wales and satisfaction of other closing conditions and is expected to occur on May 27, 2022. “We are pleased with our shareholders’ vote of confidence in the transformational combination of these companies and the potential to establish a global diagnostics leader with a broad portfolio spanning the diagnostics continuum, allowing the new company to leverage call points in complementary markets,” said Chris Smith, Chairman and Chief Executive Officer of Ortho. “We have greatly appreciated the opportunity to engage in a thoughtful and constructive dialogue with our shareholders throughout this process. We believe the combination of Quidel and Ortho will be well-positioned to accelerate growth through a broader commercial channel, stronger R&D capabilities, enhanced brand recognition, and wider overall reach by combining Quidel and Ortho’s complementary, world-class products. We are equally confident that together, we are uniquely positioned for long-term profitable growth, and we anticipate a smooth transition ahead,” Smith continued. The preliminary vote count is subject to certification by the Company’s scrutineer and independent inspector of elections. Additional information regarding the final results of the Ortho shareholder votes will be filed with the Securities and Exchange Commission on Current Report on Form 8-K and made available on Ortho’s investor website at https://ir.orthoclinicaldiagnostics.com/. About Ortho Clinical Diagnostics Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics (IVD) companies. More than 800,000 patients across the world are impacted by Ortho’s te...